3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Ovarian Neoplasms
5
Neoplasms
3
Fallopian Tube Neoplasms
3
Breast Neoplasms
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Carcinoma, Squamous Cell
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Pancreatic Adenocarcinoma
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Lung Neoplasms
1
Laryngeal Diseases
1
Glioma
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Anus Neoplasms
1
Advanced Solid Tumor, Adult
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
30
Nivolumab
15
Paclitaxel
13
Cyclophosphamide
12
Carboplatin
12
sacituzumab govitecan
8
Cisplatin
8
Capecitabine
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
fludarabine
5
durvalumab
5
avelumab
5
atezolizumab
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
5
Biopsy
5
camrelizumab
4
Specimen Handling
4
Interleukin-2
4
Injections
4
Immune Checkpoint Inhibitors
4
Docetaxel
4
toripalimab
3
talazoparib
3
Leucovorin
3
Everolimus
3
Clinical Trials, Phase II as Topic
3
Bevacizumab
3
yeast-CEA vaccine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Triple Negative Breast Neoplasms
×
niraparib
×
Clear all
NCT02657889
2022-12-01
TOPACIO
Tesaro, Inc.
Phase 1/2
Completed
122 enrolled
29 charts